A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 (Bronx)
AstraZeneca Vaccine: Study of AZD1222 for the Prevention of COVID-19 in Adults (Bronx)
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
Study Length: 24 Months
Clinic Visits: 7
IRB Number: AAAT2402
U.S. Govt. ID: NCT04516746
Contact: Logan Posey: 347-590-7280 / lp2907@cumc.columbia.edu
Additional Study Information: The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
This study is closed
Investigator
Jessica Justman, MD
Do You Qualify?
Are you 18 years old or older? Yes No
Have you ever tested positive for Sars-Co-V-2 (Covid-19)? Yes No
Are you currently pregnant? If N/A select No. Yes No
Are you preventing pregnancy (i.e. birth control)? If N/A select Yes. Yes No
Are you willing to travel to the South Bronx for participation in this study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Logan Posey
lp2907@cumc.columbia.edu
347-590-7280
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE